WO1999054314A1 - Neue diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel - Google Patents

Neue diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel Download PDF

Info

Publication number
WO1999054314A1
WO1999054314A1 PCT/EP1999/002496 EP9902496W WO9954314A1 WO 1999054314 A1 WO1999054314 A1 WO 1999054314A1 EP 9902496 W EP9902496 W EP 9902496W WO 9954314 A1 WO9954314 A1 WO 9954314A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
alkyl
substituted
hydrogen
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/002496
Other languages
German (de)
English (en)
French (fr)
Inventor
Michael Brenner
Wolf-Dietrich Bechtel
Rainer Palluk
Marion Wienrich
Thomas Weiser
Enzo Cereda
Maura Bignotti
Carlomaria Pellegrini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Italia SpA, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to AT99920661T priority Critical patent/ATE270665T1/de
Priority to MXPA00009474A priority patent/MXPA00009474A/es
Priority to EP99920661A priority patent/EP1071670B1/de
Priority to DE59909917T priority patent/DE59909917D1/de
Priority to CA002322195A priority patent/CA2322195C/en
Priority to JP2000544653A priority patent/JP4589531B2/ja
Publication of WO1999054314A1 publication Critical patent/WO1999054314A1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Definitions

  • the invention relates to new diphenyl-substituted 5-ring heterocycles, processes for their preparation and their use as medicaments.
  • X is oxygen, sulfur or NR 6 ;
  • R 1 is a Ci-CiQ-alkyl, C2-C-
  • R ⁇ and R3 which may be the same or different are hydrogen, mercapto, -NR 6 R 7 , halogen, nitro, CF3, CN, -OR 8 , -C-C ⁇ o-alkyl, C2-C ⁇ o-alkenyl or C2-C ⁇ o- lkinyl,
  • R 2 and R 3 Ce-Cio-aryl, aryl-Cj-Ce-alkyl, Cß-Ci Q-aryloxy;
  • R4 and R5 which may be the same or different are hydrogen, mercapto, -NR 6 R 7 , halogen, nitro, CF 3 , CN, -OR 8 , C-
  • R 4 and R 5 Cß-Cio-aryl, aryl-Ci-Ce-alkyl, Cß-Ci rj-aryloxy;
  • R 6 is hydrogen, C3-C6-cycloalkyl, Ci-Cio-alkyl, C2-C-
  • R6 Cö-C-jo-aryl, preferably phenyl, which may be replaced by halogen,
  • R 7 is hydrogen, C3-C6-cycloalkyl, CjC-io-alkyl, C2-C ⁇ o-alkenyl or
  • R 7 C ⁇ -C-io-aryl, preferably phenyl, which is optionally substituted by halogen,
  • R ⁇ and R 7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring, which may contain nitrogen, oxygen or sulfur as further heteroatoms, the heterocycle through a branched or unbranched alkyl group with 1 to 4 carbon atoms, through phenyl or may be substituted by benzyl;
  • R 8 is hydrogen, C-
  • Benzyl or phenyl radical which is optionally mono- or polysubstituted by OH, chlorine, bromine or OCH3, mean, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
  • X is oxygen, sulfur or NR 6 ;
  • R1 is a C - ⁇ - C alkyl radical, optionally one or more times
  • R2 and R 3 which can be the same or different, are hydrogen, SH, -NR 6 R 7 ,
  • R 2 and R 3 are phenyl, benzyl, phenyloxy
  • R 4 and R5 which may be the same or different, are hydrogen, SH, -NR 6 R 7 ,
  • R 4 and R 5 are phenyl, benzyl, phenyloxy
  • R 6 is hydrogen, C3-C6-cycloalkyl, Ci-Cß-alkyl, C2-C6-alkenyl or
  • R 6 is phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
  • C ⁇ -C4-alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted; 4 R 7 hydrogen, C 3 -C6 cycloalkyl, Cj-C ⁇ -alkyl, C2-Ce-alkenyl or
  • R 7 is phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
  • -C-C-4-alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted;
  • R6 and R 7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain nitrogen or oxygen as further heteroatoms, where the heterocycle may be substituted by C 1 -C 4 -alkyl, phenyl or benzyl;
  • R 8 is hydrogen, C - (- C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, a
  • Benzyl or phenyl radical which is optionally substituted one or more times by OH, chlorine, bromine or OCH3, mean, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
  • R1 a C ⁇
  • -C-4-alkyl radical which is formed by -CONHSO 2 R 8 , -CONR 6 R 7 , -CH NOR 8 , -NR 6 R 7 , -NHCOR 8 , -NHCONR 6 R 7 , -NHCOOR 8 ,
  • -OCONR 6 R 7 -S ⁇ 2NR 6 R 7 or is substituted by an N-oxide of the formula -NOR 6 R 7 ;
  • 5 R 2 and R 3 which may be the same or different are hydrogen, -NR 6 R 7 , fluorine, chlorine, bromine, nitro, CF3, CN, -OR 8 , -C-C4-alkyl, phenyl, benzyl or phenyloxy;
  • R 4 and R5 which can be the same or different are hydrogen, -NR 6 R 7 , fluorine, chlorine, bromine, nitro, CF3, CN, -OR 8 , C-
  • R 8 is hydrogen, C3-C6-cycloalkyl or -CC-C4-alkyl, each of which can be substituted one or more times by hydroxyl, phenyl, benzyl or C-
  • R6 phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
  • C 1 -C 4 -alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted;
  • R 7 is hydrogen, C 1 -C 8 -cycloalkyl or C 1 -C 4 -alkyi, each of which can be substituted one or more times by hydroxyl, phenyl, benzyl or C 1 -C 4 -alkoxy,
  • R 7 is phenyl which may be replaced by fluorine, chlorine, bromine, -OR 8 ,
  • -C4-alkyl preferably -CH3, -SO3H, or -COOR 8 may be substituted; or
  • R6 and R 7 together with the nitrogen atom form a saturated or unsaturated 5- or 6-membered ring which may contain nitrogen or oxygen as further heteroatoms, where the heterocycle can be substituted by C 1 -C 4 -alkyl, phenyl or benzyl;
  • R 8 is hydrogen, C 1 -C 4 -alkyl, a benzyl or phenyl radical which is optionally substituted one or more times by OH, chlorine, bromine or OCH3, optionally in the form of their racemates, their enantiomers, in the form their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts. 6 According to the invention, preference is furthermore given to compounds of the general formula (I) in which
  • Triazole, triazoline, triazoiidine, oxazole, oxazoline, oxadiazole but not 1, 2,4-oxadiazole, isoxazole or isoxazoline, each one or more times by Cj-C4-alkoxy, OH, O or C-
  • -C4-alkyl can be substituted, wherein the Cj-C4-alkyl radical in turn can be substituted by fluorine, chlorine, bromine, OH or -NR 6 R 7 ;
  • R 1 Ci -C4 alkyl which is substituted by -NR 6 R 7 or by an N-oxide of the formula - NOR 6 R 7 ;
  • R 2 and R 3 which may be the same or different, are hydrogen, -NR 6 R 7 , fluorine,
  • R 4 and R5 which may be the same or different are hydrogen, -NR 6 R 7 , fluorine,
  • R6 is hydrogen or C 1 -C 4 -alkyl which is substituted one or more times by hydroxy
  • Phenyl, benzyl or C 1 -C 4 alkoxy can be substituted
  • R 7 is hydrogen or C-
  • Phenyl, benzyl or C-i-C-t-alkoxy may be substituted, or
  • R6 and R 7 together with the nitrogen atom form a saturated or unsaturated heterocycle selected from the group pyrrole, pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, the heterocycles mentioned being optionally by Methyl, ethyl, propyl or benzyl may be substituted; 7 R 8 is hydrogen, C 1 -C 4 -alkyl, benzyl or phenyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
  • A is a radical selected from the group pyrrole, pyrazole, imidazole, imidazoline, imidazolidine, triazole, oxazole, oxazoiin, isoxazole, 1, 3,4-
  • R 1 is C 1 -C 4 alkyl which is substituted by -NR 6 R 7 ;
  • R 2 and R 3 are hydrogen
  • R 4 and R 5 are hydrogen
  • R6 is hydrogen, methyl, ethyl, propyl or butyl
  • R 7 is hydrogen, methyl, ethyl, propyl or butyl; or
  • R6 and R 7 together with the nitrogen atom form a saturated or unsaturated heterocycle selected from the group piperidine,
  • Piperazine or morpholine optionally substituted by methyl, ethyl or
  • Benzyl may be substituted, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts. 8 Of particular interest are compounds of the general formula (I) in which
  • A is a radical selected from the group pyrrole, pyrazole, imidazole,
  • R1 is an ethyl or propyl radical which is substituted by -NR 6 D R7
  • R 2 and R 3 are hydrogen
  • R 4 and R 5 are hydrogen
  • R6 is hydrogen, methyl, ethyl, propyl or butyl
  • R 7 is hydrogen, methyl, ethyl, propyl or butyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, and, if appropriate, their pharmacologically acceptable acid addition salts.
  • R " ! Is an ethyl or propyl radical which is substituted by -NR 6 R 7 ;
  • R 2 and R 3 are hydrogen
  • R 4 and R 5 are hydrogen
  • R 6 is hydrogen, methyl, ethyl, propyl or butyl
  • R 7 is hydrogen, methyl, ethyl, propyl or butyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, optionally in the form of their tautomers, and, if appropriate, their pharmacologically acceptable acid addition salts.
  • R 1 is an ethyl or propyl radical which is substituted by -NR 6 R 7 ;
  • R 2 and R 3 are hydrogen
  • R 4 and R 5 are hydrogen
  • R 6 is hydrogen, methyl, ethyl, propyl or butyl
  • R 7 is hydrogen, methyl, ethyl, propyl or butyl, optionally in the form of their racemates, their enantiomers, in the form of their diastereomers and their mixtures, optionally in the form of their tautomers, and, if appropriate, their pharmacologically acceptable acid addition salts.
  • R 2 and R 3 are hydrogen
  • R 4 and R 5 are hydrogen
  • R 6 is methyl; 12 R 7 is methyl, optionally in the form of their racemates
  • Enantiomers in the form of their diastereomers and their mixtures, if appropriate in the form of their tautomers, and, if appropriate, their pharmacologically acceptable acid addition salts.
  • alkyl groups are branched and unbranched alkyl groups with ibis 10 carbon atoms, preferably 1-4 carbon atoms, for example: methyl, ethyl, n-propyl, iso- Propyl, butyl, iso-butyl, sec. Butyl, tert-butyl, pentyl, iso-pentyl, hexyl, heptyl and octyl.
  • Me, Et, Bu or tBu are also used to denote the groups methyl, ethyl, butyl or tert-butyl.
  • Alkenyl groups are branched and unbranched alkenyl groups with 2 to 10 carbon atoms, preferably 2 to 3 carbon atoms, provided that they have at least one double bond, for example also the alkyl groups mentioned above, provided that they have at least one double bond, such as for example vinyl (as long as no volatile enamines or enol ethers are formed), propenyl, iso-propenyl, butenyl, pentenyl, hexenyl.
  • Alkynyl groups are alkynyl groups with 2 to 10 carbon atoms if they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl.
  • Cycloalkyl radicals having 3 to 6 carbon atoms are, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which can also be substituted by branched or unbranched alkyl having 1 to 4 carbon atoms, hydroxy, and / or halogen or as previously defined.
  • Halogen is generally referred to as fluorine, chlorine, bromine or iodine.
  • aryl stands for an aromatic ring system with 6 to 10 carbon atoms which, unless otherwise described, can carry, for example, one or more of the substituents mentioned below: Ci-C ⁇ -alkyl, C-1-C5-alkyloxy, halogen, hydroxy, Mercapto, amino, alkylamino, dialkylamino, CF3, cyano, nitro, -CHO, -COOH, -COO-C-
  • the preferred aryl radical is phenyl.
  • N-linked cyclic radicals of the general formula NR ⁇ R 7 are: pyrrole, pyrroline, pyrrolidine, 2-methylpyrrolidine, 3-methylpyrrolidine, piperidine, piperazine, N-methylpiperazine, N-ethylpiperazine, N- (n-propyl ) -piperazine,
  • the present invention describes compounds which surprisingly have a high affinity for the following receptor type: "Na + channel site 2" binding site. In addition, these compounds show antagonistic activity at the AMPA receptor. Based on these findings, the compounds according to the invention can be used in neurodegenerative diseases and brain ischemia of various origins.
  • HCl gas is introduced into a solution of 100 g of benzonitrile and 60 ml of ethanol over a period of about 3 hours (weight gain: about 65 g).
  • the mixture obtained is then left to stand at -25 ° C. for 6 days.
  • aqueous phase is made alkaline with aqueous ammonia solution and twice with 17 dichloromethane extracted.
  • the organic phase is dried over sodium sulfate, concentrated in vacuo and chromatographed on silica gel (methanol). Yield: 500 mg (41%), light oil; Mp (fumarate): 184-186 ° C;
  • a solution of 0.6 g of 1- (2-hydroxyphenyl) -5-methyl-3-phenyl-1, 2,4-triazole in 5 ml of 1,4-dioxane and a suspension of 0.27 are then slowly added g of potassium tert-butoxide in 5 ml of 1,4-dioxane.
  • the mixture obtained in this way is stirred at about 100 ° C. for 3 hours.
  • the solvent is then distilled off in vacuo, the remaining residue is taken up in ethyl acetate and the organic phase obtained in this way is extracted first with water and then with 2N HCl solution (aq.).
  • the aqueous phases are made alkaline with aqueous ammonia solution and extracted with ethyl acetate.
  • step b 3.4 g of the imidohydrazide prepared according to Example 5 (step b) are taken up with 12.1 g of triethyl orthoacetate in 50 ml of anhydrous ethanol and heated to reflux for 6 hours. After cooling to room temperature, the solvent is distilled off in vacuo and the remaining residue is taken up in diethyl ether. The organic phase thus obtained is washed three times with water, dried over MgSO 4 and the solvent is distilled off in vacuo. The remaining crude product is purified by chromatography on silica gel (toluene: ethyl acetate 80:20). Yield: 2 g (53%), slightly brownish oil;
  • Example 8 4- (2-r2 (N, N-Dimethylamino) ethyl-phenyl) -2-phenyl-1,3-oxazole
  • step (d) 4- (2-Hydroxyphenyl) -2-phenyl-1, 3-oxazole 0.7 g of 4- (2-benzyloxyphenyl) -2-phenyl-1, 3-oxazole according to step (d), 30 ml of tetrahydrofuran in In the presence of 0.1 g Pd / C catalyst hydrogenated at 20-60 ° C (5 bar). After the catalyst has been separated off, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (dioxane: hexane 1: 5). Yield: 0.5 g (99%);
  • step (a) 1 - (2-Benzyloxy-phenyl) -2-bromoethanone: 2.9 g of 2-benzyloxyacetophenone (Example 8, step (a)) are taken up in 50 ml of anhydrous chloroform and at about 2 ° C. with stirring slowly added a solution of 2.1 g bromine in 10 ml anhydrous chloroform. After complete conversion, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (toluene). Yield: 2.3 g (59%);
  • step (c) 2.2 g of 4- (2-benzyloxyphenyl) -1-tert.butoxycarbonyl-2-phenyl-1, 3-imidazole according to step (c) are added in 35 ml of tetrahydrofuran in the presence of 0.2 g of Pd / C catalyst Room temperature hydrogenated (5 bar). After the catalyst has been separated off, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (toluene). Yield: 0.75 g (43%);
  • Example 12 5- ⁇ 2- [2 (N, N-Dimethylamino) ethnoxy-phenyl ⁇ -3-phenyl-1, 3,4-oxadiazol-2-one
  • Example 3 in analogy to Example 12 (stage a).
  • MeO a) 2- (2-methoxyphenyl) amino-1-phenyl-ethane-1-one A mixture of 10 g of 2-bromoacetophenone, 5.62 ml of 2-methoxyaniline and 5.85 g of Na2CÜ3 in ethanol is stirred for 18 hours . After dilution with water, the mixture is stirred for a further 30 minutes and the mixture is filtered. After washing the separated solid with water and hexane, 9.7 g of 2- (2-methoxyphenyl) amino-1-phenyl-ethan-1-one remain as a green-yellow solid. No further cleaning takes place.
  • Example 18 4- (2- 2 (N.N-dimethylamino) ethvi1oxy-phenyl ⁇ -1-phenyl-pyrazole
  • Example 17 in analogy to Example 12 (stage a). Mp: 205-208 ° C (diethyl ether);
  • Example 20 1- ⁇ 2-f2 (N, N-Dimethylamino) ethyl-phenyl) -4-phenyl-1,3-dihydro-imidazol-2-one yy
  • Example 22 4- ⁇ 2-r2 (N, N-Dimethylamino) ethyl1oxy-phenyl ⁇ -1-phenyl-1, 3-dihydro-imidazol-2-one
  • step (c) 0.55 g 5- (2-benzyloxyphenyl) -2-phenyl-1, 3-oxazole according to step (c) are dissolved in 30 ml tetrahydrofuran in the presence of 0.1 g Pd / C catalyst (10%) at approx. Hydrogenated at 60 ° C (5.7 bar). After the catalyst has been separated off, the solvent is distilled off in vacuo and the remaining residue is chromatographed on silica gel (dioxane: hexane 3: 5). Yield: 0.38 g (95%);
  • the compounds according to the invention show an affinity for or activity on different receptor types and have a neuroprotective effect.
  • histamine and serotonin are of particular importance as neurotransmitters.
  • concentrations of calcium and sodium ions in particular are changed.
  • Brain lesions that can be induced with such substances are comparable to those associated with epilepsy and other neurodegenerative diseases - such as e.g. Huntington's disease and Alzheimer's disease - occur.
  • Substances and ions that inhibit the activity of the glutamate receptors and the ion channel connected to this receptor - such as competitive and non-competitive antagonists of excitatory amino acids - protect brain cells from hypoxic or ischemic damage.
  • the detection of the affinity for the "Na + Kanal site 2" binding site was carried out as described by GB Brown (J. Neurosci. 6 (1986) 2064). The testing was typically carried out at a test concentration of 10 ⁇ M.
  • the compounds of the general formula (I) can be used for neurodegenerative diseases and brain ischemia of various origins. These include, for example: status epilepticus, hypoglycemia, hypoxia, anoxia, brain trauma, brain edema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotension, heart attack, intracranial pressure (increased intracranial pressure), ischemic and hemorrhagic strokes, global heart Polyneuropathy, tinitus, perinatal asphyxia, psychosis, schizophrenia, depression and Parkinson's disease.
  • the compounds of the general formula (I) can be used alone or in combination with other active compounds according to the invention, optionally also in combination with other pharmacologically active compounds. Suitable forms of use are, for example, tablets, capsules, suppositories, solutions, in particular solutions for injection (SC, IV, IM) and infusion, juices, emulsions or dispersible powders.
  • the proportion of the pharmaceutically active compound (s) should in each case be in the range from 0.1 to 90% by weight, preferably 0.5 to 50% by weight, of the total composition, i.e. in amounts sufficient to reach the dosage range given below.
  • Corresponding tablets can be mixed, for example, by mixing the active ingredient (s) with known auxiliaries, for example inert diluents such as calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents to achieve the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • auxiliaries for example inert diluents such as calcium carbonate, calcium phosphate or milk sugar, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc, and / or agents to achieve the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
  • auxiliaries for example inert diluents
  • coated tablets can be produced by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the core can also consist of several layers in order to achieve a depot effect or to avoid incompatibilities.
  • the coated tablet shell can also consist of several layers in order to achieve a depot effect, wherein the auxiliaries mentioned above for the tablets can be used.
  • 45 juices of the active substances or combinations of active substances according to the invention can additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar as well as a taste-improving agent, for example flavorings such as vanillin or orange extract. They can also contain suspending aids or thickeners, such as sodium carboxymethyl cellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
  • Injection and infusion solutions are used in the usual way, e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvents , manufactured and filled into injection bottles or ampoules or infusion bottles.
  • isotonants e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvent
  • the capsules containing one or more active ingredients or combinations of active ingredients can be produced, for example, by mixing the active ingredients with inert carriers, such as milk sugar or sorbitol, and encapsulating them in gelatin capsules.
  • inert carriers such as milk sugar or sorbitol
  • Suitable suppositories can be produced, for example, by mixing them with carrier agents, such as neutral fats or polyethylene glycol or its derivatives.
  • carrier agents such as neutral fats or polyethylene glycol or its derivatives.
  • auxiliary substances are water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils
  • e.g. peanut or sesame oil monofunctional or polyfunctional alcohols (e.g. ethanol or glycerin), carriers such as e.g. natural rock flours (e.g. kaolins, clays, talc, chalk) synthetic rock flours (e.g. highly disperse silica and silicates), sugar (e.g. cane, milk and dextrose) emulsifiers (e.g. lignin, sufite liquor, methyl cellulose, starch and
  • natural rock flours e.g. kaolins, clays, talc, chalk
  • synthetic rock flours e.g. highly disperse silica and silicates
  • sugar e.g. cane, milk and dextrose
  • emulsifiers e.g. lignin, sufite liquor, methyl cellulose, starch and
  • Polyvinylpyrrolidone and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate).
  • lubricants e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate.
  • the application is carried out in the usual way, preferably parenterally - in particular by infusion - intravenously.
  • the tablets can of course also contain additives, such as sodium citrate, calcium carbonate and dicalcium phosphate, in addition to the carrier substances mentioned Contain 46 different additives, such as starch, preferably potato starch, gelatin and the like.
  • Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
  • the active ingredients can be mixed with various flavor enhancers or colorants.
  • solutions of the active ingredients can be used using suitable liquid carrier materials.
  • the dosage for intravenous use is 1 - 1000 mg per hour, preferably between 5 - 500 mg per hour.
  • the finely ground active ingredient, milk sugar and part of the corn starch are mixed together.
  • the mixture is sieved, whereupon it is moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
  • the granules, the rest of the corn starch and the magnesium stearate are sieved and mixed together.
  • the mixture is compressed into tablets of a suitable shape and size.
  • the finely ground active ingredient, part of the corn starch, milk sugar, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sieved and processed with the rest of the corn starch and water to form a granulate which is dried and sieved.
  • the sodium carboxymethyl starch and the magnesium stearate are added, and the mixture is mixed and pressed into tablets of a suitable size.
  • the active ingredient is dissolved in water at its own pH or, if appropriate, at pH 5.5 to 6.5, sodium chloride is added as the isotonic agent, the solution obtained is filtered pyrogen-free and the filtrate is filled into ampoules under aseptic conditions, which are then sterilized and sealed .
  • the ampoules contain 5 mg, 25 mg and 50 mg of active ingredient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/EP1999/002496 1998-04-17 1999-04-14 Neue diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel Ceased WO1999054314A1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT99920661T ATE270665T1 (de) 1998-04-17 1999-04-14 Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
MXPA00009474A MXPA00009474A (es) 1998-04-17 1999-04-14 Nuevos heterociclos de 5 anillos sustituidos con difenilo, procedimientos para su preparacion, asi como su empleo como medicamentos.
EP99920661A EP1071670B1 (de) 1998-04-17 1999-04-14 Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE59909917T DE59909917D1 (de) 1998-04-17 1999-04-14 Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
CA002322195A CA2322195C (en) 1998-04-17 1999-04-14 Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
JP2000544653A JP4589531B2 (ja) 1998-04-17 1999-04-14 新規ジフェニル置換5員環複素環化合物、それらの製造方法及び薬物としてのそれらの使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19816880A DE19816880A1 (de) 1998-04-17 1998-04-17 Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IT98MI000818A IT1300055B1 (it) 1998-04-17 1998-04-17 Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
DE19816880.2 1998-04-17
ITMI98A000818 1998-04-17

Publications (1)

Publication Number Publication Date
WO1999054314A1 true WO1999054314A1 (de) 1999-10-28

Family

ID=26045525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/002496 Ceased WO1999054314A1 (de) 1998-04-17 1999-04-14 Neue diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel

Country Status (10)

Country Link
US (1) US6255327B1 (cg-RX-API-DMAC7.html)
EP (1) EP1071670B1 (cg-RX-API-DMAC7.html)
JP (1) JP4589531B2 (cg-RX-API-DMAC7.html)
AT (1) ATE270665T1 (cg-RX-API-DMAC7.html)
CA (1) CA2322195C (cg-RX-API-DMAC7.html)
DE (2) DE19816880A1 (cg-RX-API-DMAC7.html)
ES (1) ES2224652T3 (cg-RX-API-DMAC7.html)
IT (1) IT1300055B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA00009474A (cg-RX-API-DMAC7.html)
WO (1) WO1999054314A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070708A1 (en) * 1999-07-21 2001-01-24 F. Hoffmann-La Roche Ag Triazole and imidazole derivatives
WO2002060877A1 (en) * 2001-01-29 2002-08-08 F. Hoffmann-La Roche Ag Imidazole derivatives
US9051342B2 (en) 2004-10-13 2015-06-09 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases
CN106573894A (zh) * 2014-08-13 2017-04-19 日本曹达株式会社 二芳基咪唑化合物和有害生物防除剂

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
JP2007527917A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2008131148A1 (en) * 2007-04-19 2008-10-30 The Trustees Of The University Of Pennsylvania Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
CN102060798A (zh) * 2011-01-04 2011-05-18 复旦大学 2-(1-氢-4-四唑)-4′- 甲基联苯及其衍生物的合成方法
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2152345A1 (en) * 1971-09-06 1973-04-27 Roussel Uclaf Alpha-(2-thiazolyl)oxyalkanoic acids and derivatives - - with analgesic,antiinflammatory and antipyretic activity
EP0248594A2 (en) * 1986-05-29 1987-12-09 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same
EP0513387A1 (en) * 1990-11-30 1992-11-19 Otsuka Pharmaceutical Co., Ltd. Active oxygen inhibitor
DE19528189A1 (de) * 1995-08-01 1997-02-06 Basf Ag Benzolderivate mit einem heterocyclischen Rest
WO1998015274A1 (en) * 1996-10-07 1998-04-16 Eli Lilly And Company Novel compounds useful as neuro-protective agents
WO1998017652A1 (de) * 1996-10-18 1998-04-30 Boehringer Ingelheim Pharma Kg Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
WO1998027108A2 (en) * 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5305E (fr) * 1905-06-17 1906-02-22 Edouard Pellorce Appareil électrique pour l'allumage des moteurs à explosion
DE1545806A1 (de) * 1951-01-28 1969-11-27 Hoechst Ag Verfahren zur Herstellung von heterocyclischen Verbindungen
FR1356901A (fr) * 1958-03-13 1964-04-03 Nouveaux aminoétheroxydes, aminothioéthers et aminoesters dérivés du pyrrole, etleur procédé de préparation
FR2244462A1 (en) * 1973-09-25 1975-04-18 Delalande Sa Antihypertensive, 5-hydroxy methyl 1,2,4-triazoles - prepd. from aniline and a hydroxy methyl 1,3,4-oxadiazole
SU753084A1 (ru) * 1979-03-23 1983-01-23 Ростовский Ордена Трудового Красного Знамени Государственный Университет Способ получени 1-[2-алкил(аралкил)аминоарил -4-арилимидазолов общей формулы
US4370336A (en) * 1979-06-11 1983-01-25 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives as antifertility agents
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JP2928307B2 (ja) * 1989-02-03 1999-08-03 エーザイ株式会社 ピロリジン誘導体
FR2678938B1 (fr) * 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5411977A (en) * 1993-03-31 1995-05-02 The Dupont Merck Pharmaceutical Company Substituted 2,5-diaryl-4-isothiazolin-3-ones as antiinflammatory and antithrombotic agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2152345A1 (en) * 1971-09-06 1973-04-27 Roussel Uclaf Alpha-(2-thiazolyl)oxyalkanoic acids and derivatives - - with analgesic,antiinflammatory and antipyretic activity
EP0248594A2 (en) * 1986-05-29 1987-12-09 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same
EP0513387A1 (en) * 1990-11-30 1992-11-19 Otsuka Pharmaceutical Co., Ltd. Active oxygen inhibitor
DE19528189A1 (de) * 1995-08-01 1997-02-06 Basf Ag Benzolderivate mit einem heterocyclischen Rest
WO1998015274A1 (en) * 1996-10-07 1998-04-16 Eli Lilly And Company Novel compounds useful as neuro-protective agents
WO1998017652A1 (de) * 1996-10-18 1998-04-30 Boehringer Ingelheim Pharma Kg Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
WO1998027108A2 (en) * 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C P TAYLOR ET AL: "TRENDS IN PHARMACOLOGICAL SCIENCES", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 16, 1 September 1995 (1995-09-01), pages 309 - 316, XP002090490, ISSN: 0165-6147 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070708A1 (en) * 1999-07-21 2001-01-24 F. Hoffmann-La Roche Ag Triazole and imidazole derivatives
US6265426B1 (en) 1999-07-21 2001-07-24 Hoffmann-La Roche Inc. Triazole derivatives
WO2002060877A1 (en) * 2001-01-29 2002-08-08 F. Hoffmann-La Roche Ag Imidazole derivatives
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US6667335B2 (en) 2001-01-29 2003-12-23 Hoffmann-La Roche Inc. Imidazole derivatives
US6683097B2 (en) 2001-01-29 2004-01-27 Hoffmann-La Roche Inc. Imidazole derivatives
US9051342B2 (en) 2004-10-13 2015-06-09 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases
CN106573894A (zh) * 2014-08-13 2017-04-19 日本曹达株式会社 二芳基咪唑化合物和有害生物防除剂

Also Published As

Publication number Publication date
ES2224652T3 (es) 2005-03-01
JP2002512235A (ja) 2002-04-23
US6255327B1 (en) 2001-07-03
DE19816880A1 (de) 1999-10-21
EP1071670B1 (de) 2004-07-07
IT1300055B1 (it) 2000-04-05
CA2322195C (en) 2008-02-26
ITMI980818A1 (it) 1999-10-17
CA2322195A1 (en) 1999-10-28
DE59909917D1 (de) 2004-08-12
EP1071670A1 (de) 2001-01-31
MXPA00009474A (es) 2002-08-12
JP4589531B2 (ja) 2010-12-01
ATE270665T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
EP0934288B1 (de) Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3788385T2 (de) Pyrimidin-Derivate.
EP0136658B1 (de) 1-Benzyl-aminoalkyl-pyrrolidinone und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel
DD237510A5 (de) Verfahren zur herstellung von substituierten imidazo-(1,5-a)pyridin-derivaten
EP1071670B1 (de) Diphenyl-substituierte 5-ring-heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE2235544A1 (de) 1-alkyl-3,5-disubstituierte 1,2,4triazolderivate und verfahren zu deren herstellung
EP1071671B1 (de) Triazolone mit neuroprotektiver wirkung
DE1958201A1 (de) Neue substituierte N-Allyl-2-arylamino-imidazoline-(2) und Verfahren zu deren Herstellung
DE3435745A1 (de) 2-(3-(4-(3-phenyl)-1-piperazinyl)propyl)-2,4-dihydro-3h-1,2,4-triazol-3-on verbindungen, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
EP1611107A1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
DE60010126T2 (de) Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h(1,2,4)triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE2633679A1 (de) 4,5-dihydro-2-niederalkoxycarbonylamino-4-phenylimidazole und derivate davon mit substituierter phenylgruppe
DD156808A5 (de) Verfahren zur herstellung von 1,1-diphenyl 1-2-(1.2.4.-ariazol-1-yl)-aethan-1-oben
EP0200947B1 (de) 1,3-Disubstituierte Imidazoliumsalze
CH618438A5 (cg-RX-API-DMAC7.html)
EP0298921B1 (de) 1,2-Benzisoxazole und 1,2-Benzisothiazole
DD282457A5 (de) Verfahren zur herstellung neuer heterocyclischer derivate
EP1077950B1 (de) Neue diphenyl-substituierte 6-ring heterocyclen, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE68913167T2 (de) Indol-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
DE69707080T2 (de) Pyrrolidinonderivate und ihre Verwendung als antipsychotische Arzneimittel
EP0037471B1 (de) 1-Aroyl-2-phenylamino-2-imidazoline, ihre Herstellung und diese enthaltende Arzneimittel
DE2709842A1 (de) Benzodiazepine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0129509B1 (de) Triazol(2,3-c)(1,3)benzodiazepine, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Verwendung
EP0478941B1 (de) Arzneimittel welche substituierte 2-Cyclohexen-1yl-amin-Derivate enthalten und ihre Verwendung zur Bekämpfung von Krankheiten
AT362358B (de) Verfahren zur herstellung von neuen 6-aryl-2,3, 6,7-tetrahydro-5h-pyrrolo (1,2-a)imidazolen und von deren saeureadditionssalzen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999920661

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2322195

Country of ref document: CA

Ref country code: CA

Ref document number: 2322195

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009474

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999920661

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999920661

Country of ref document: EP